Company / R&D Expense
RxSight, Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$29.1M
FY2025
5-year range
$21.9M / $29.1M
FY2021-FY2025
Trend
+11.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $26M to $29M over the past 2 years.
Based on SEC 10-K filings.
$29M in FY2025 with a 3-year CAGR of +5.8%.
Improved from $26M to $29M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, r&d expense increased 11.8% year-over-year.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.59 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.1M | +11.8% |
| FY2024 | $26.0M | +0.0% |
| FY2023 | $26.0M | +6.0% |
| FY2022 | $24.5M | +11.7% |
| FY2021 | $21.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026